凌科药业（杭州）有限公司 Lingke Pharmaceutical
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002 2021-08-12 08:00
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003 2021-06-25 15:11
Lynk Pharmaceuticals enters exclusive licensing agreements with Kobe University and with RIKEN Research Institute to develop RAS inhibitors with a novel MOA 2020-07-27 07:00
1 2